That is, unless you're watching a Mike Schur show. The creative force behind comedies such as "Parks and Recreation," "Brooklyn Nine-Nine," and "The Good Place" has a knack for creating hit TV ...

Mike Schur is known for clever, kind-hearted TV shows like "Parks and Recreation" and "The Good Place." His latest Netflix series, "A Man on the Inside," is a sweet, emotional comedy about aging.

He’s in a good place. Mike Schur, best known for writing on “The Office” and creating “Parks and Recreation,” “Brooklyn Nine-Nine” and “The Good Place,” enters the world of ...

He’s not going back to Scranton. Mike Schur, who was a producer and writer on “The Office,” before he went on to co-create hit comedies like “Parks and Recreation” and “Brooklyn Nine ...

“We decided late in the game to name every episode after a famous spy story,” Schur said in an interview with IndieWire, adding he didn’t know offhand who came up with the title for Episode 1.

Click to share on Facebook (Opens in new window) Click to share on Twitter (Opens in new window) Not only has Schur built an audience, but he has formed close bonds with many of the actors ...

Michael Schur at the Man on the Inside Los Angeles premiere at Netflix Tudum Theater on November 10, 2024 in Los Angeles, California. Getty Images for Netflix “The documentary was a pretty good ...

A Man on the Inside creator Mike Schur has a hilarious response to anyone hoping for guests in a second season. Speaking with Decider about the Ted Danson-led comedy, Schur — who is married to ...

Among the many delights in Michael Schur’s new Netflix comedy, “A Man on the Inside,” there’s an aptly covert one that may go overlooked. Actually, there’s eight. Depending on how you watch Netflix, ...

Graph-based semi-supervised learning methods combine the graph structure and labeled data to classify unlabeled data. In this work, we study the effect of a noisy oracle on classification. In ...

The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...